News
← Older posts Newer posts →Stryker’s 2010 Innovator of the Year Brian Hess Joins InVivo Therapeutics as Director of Product Development
Moves from Stryker to Translate InVivo’s Biomaterials for Acute and Chronic Neurological Injuries to Market CAMBRIDGE, Mass. (February 22, 2012) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), announced today that former Stryker biomaterials product development specialist, Brian Hess, has joined InVivo as its Director of Product Development. As Director of Product Development, Hess will be [...]
Posted in Investor Relations, News, Press Releases | Leave a comment
InVivo Therapeutics’ CEO Frank Reynolds Scheduled to Appear on Fox News First and San Antonio Living
CAMBRIDGE, Mass. (February 17, 2012) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds is scheduled to appear on San Antonio’s Fox News First on KABB-TV on Wednesday, February 22nd during their 7:00 AM (CST) newscast. Reynolds is [...]
Posted in Investor Relations, News, Press Releases | Leave a comment
InVivo Therapeutics Announces Full Exercise of Over-Allotment Option
CAMBRIDGE, Mass. (February 21, 2012) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries, today announced the full exercise of the over-allotment option granted to the underwriters to purchase 1,242,236 additional shares, at a public offering price of $2.10 per share, in connection with its [...]
Posted in Investor Relations, News, Press Releases | Leave a comment
InVivo Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. (February 16, 2012) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries, today announced the pricing of an underwritten public offering of 8,281,574 shares of its common stock, offered at a price to the public of $2.10 per share, for gross proceeds of [...]
Posted in Investor Relations, News, Press Releases | Leave a comment
InVivo Therapeutics’ CEO Frank Reynolds Scheduled to Appear on KSTP-TV (ABC) and KMSP-TV (FOX) in Minneapolis To Discuss Paralyzing Injuries To Local High School Hockey Players
CAMBRIDGE, Mass. (January 18, 2012) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds is scheduled to appear on Minneapolis’ ABC affiliate, KSTP-TV, on Sunday, January 15th during the 8:00 AM (CST) newscast and the FOX affiliate, KMSP-TV, [...]
Posted in Investor Relations, News, Press Releases, Uncategorized | Leave a comment
InVivo Therapeutics, Geisinger Health System to Conduct Preclinical Study of Injectable Scaffold for Peripheral Nerve Injury For FDA Submission
CAMBRIDGE, Mass. and DANVILLE, Pa. (January 17, 2012) — InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), and Geisinger Health System today announced a research collaboration to conduct a preclinical study using InVivo’s injectable biocompatible hydrogel for the treatment of chronic pain caused by [...]
Posted in Investor Relations, News, Press Releases | Leave a comment
InVivo Therapeutics to Present at Noble Financial Capital Markets’ Eighth Annual BOCEMb Equity Conference
CAMBRIDGE, Mass. – January 11, 2012 – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced CEO Frank Reynolds will present InVivo’s most recent breakthroughs and provide a business update to potential investors at BOCEMb Noble Financial Capital Markets’ Eight Annual Equity Conference [...]
Posted in Investor Relations, News, Press Releases | Leave a comment
InVivo Therapeutics’ CEO Frank Reynolds Scheduled to Appear on FOX40 Live in Sacramento
CAMBRIDGE, Mass. (January 10, 2012) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds is scheduled to appear on KTXL-TV’s FOX40 Live on Wednesday, January 11th during their 8:00 AM (PST) newscast. InVivo Therapeutics has pioneered a new [...]
Posted in Investor Relations, News, Press Releases | Leave a comment
InVivo Therapeutics to Present at the Fourth Annual BioTech Showcase 2012
CAMBRIDGE, Mass. – January 4, 2012 – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced CEO Frank Reynolds will present InVivo’s most recent breakthroughs and provide a business update to potential investors during the Fourth Annual BioTech Showcase. The conference is scheduled [...]
Posted in Investor Relations, News, Press Releases | Leave a comment
InVivo Therapeutics Co-Founder Dr. Robert S. Langer Awarded Annual Innovation Award from The Economist
CAMBRIDGE, Mass. (December 12, 2011) — InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today congratulates Robert S. Langer, Sc.D., InVivo co-founder and member of the Company’s Scientific Advisory Board, for his selection as the recipient of the 2011 The [...]
Posted in Investor Relations, News, Press Releases | Leave a comment ← Older posts Newer posts →